Novartis bets big on gene therapy with $8.7 billion AveXis deal – Reuters
Reuters |
Novartis bets big on gene therapy with $8.7 billion AveXis deal
Reuters Narasimhan is counting on AveXis's main drug, AVXS-101, for deadly spinal muscular atrophy (SMA), as well as the Illinois-based company's gene therapy expertise and manufacturing capabilities, to bolster Novartis's neuroscience business, one of the … |
